Detalhe da pesquisa
1.
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Proc Natl Acad Sci U S A
; 118(28)2021 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162739
2.
Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
Viruses
; 16(3)2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38543782
3.
Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
Viruses
; 15(5)2023 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243266
4.
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome.
Nat Commun
; 13(1): 4182, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853863
5.
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
J Clin Invest
; 132(24)2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36301637
6.
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
Front Immunol
; 12: 772240, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34858430
7.
A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice.
Viruses
; 12(1)2019 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31878180